Emergent BioSolutions (NYSE:EBS) initiates two new programs aimed at treating and preventing coronavirus infection based on its hyperimmune platforms.
Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) for the potential treatment of severely ill hospitalized patients and protection for at-risk people.
Equine-derived polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-EIG) for the potential treatment of severely ill hospitalized patients.
Both candidates will be derived from plasma, humans with anti-SARS-CoV-2 antibodies and horses immunized with anti-SARS-CoV-2 antibodies.
